• Special Issue Topic

    Off-Label Drugs and -Omics Data in Cancer Treatment

    Submission Deadline: June 30, 2021

    Guest Editors

    Dr. Luca Agnelli E-Mail

    Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

    Research Keywords: lymphoid malignancies; bioinformatics and biostatistics in cancer; -omics analyses; NGS; non-coding RNA

    Dr. Giancarlo Pruneri  E-Mail

    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    About the Special Issue

    The knowledge about cancer has improved on the basis of -omics studies. The integration of genetic information about cancers with data on how the cancers respond to target based-therapy help to define optimum cancer treatment. As a consequence, in the last decades, targeted therapies led to unprecedented clinical benefit in first-line therapies, as well as in patients with aggressive or advanced neoplasms bearing specific genomic alterations (gene mutations, amplifications, translocations, microsatellite instability). Although it would be desirable to increase the number of clinical trials and standardized treatments, several factors influence so far the choice of therapies, including the non-trivial aspect of the cost-effective manageability by the Healthcare National Institutions. For this reason, several non-standard treatments are commonly considered, and off-label drug usage is a common practice in treating cancer, in most cases based on physician choice. This common clinical practice suffers from a lack of knowledge base for proper cancer drug selections. The present issue is aimed at focusing on all the aspects (clinical evidence, procedures, scientific hypothesis, and investigations) involving off-label drugs for cancer treatment in the context of -omics data.

    Keywords: Off-label drugs; omics data; real-world cancer treatments; (targeted) NGS; biomarkers

    Call for Papers

    Published Articles

    Open Access
    The evolving role and utility of off-label drug use in multiple myeloma
    The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 1 [...] Read more.
    James H Stoeckle ... Gareth J Morgan
    Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:355–373
    DOI: https://doi.org/10.37349/etat.2021.00050
    Times Cited: 0
    Open Access
    Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
    Multiple myeloma (MM), the second most common hematologic cancer, is caused by accumulation of aberrant plasma cells in the bone marrow. Its molecular causes are not fully understood and its great h [...] Read more.
    Sara Ovejero, Jerome Moreaux
    Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:65–106
    DOI: https://doi.org/10.37349/etat.2021.00034
    Times Cited: 0